CardioGenesis, Eclipse TMR, PMR Data Updates To Be Presented At ACC
This article was originally published in The Gray Sheet
Executive Summary
Six-month data on 221 patients enrolled in CardioGenesis' U.S. trial of the Axcis percutaneous transmyocardial revascularization (PMR) system show negligible morbidity and a positive safety profile for treatment of no option Class III or IV angina patients.